Phosphoinositide 3-kinase mutations in breast cancer: A "good" activating mutation?

Serena Di Cosimo, José Baselga

Research output: Contribution to journalArticle

Abstract

Gain-of-function mutations in the catalytic subunit of phosphoinositide-3- kinase (PI3KCA) occur frequently in breast cancer. Kalinsky and colleagues show that PI3KCA mutations are associated with favorable clinicopathologic features and better clinical outcome, including survival. These findings will have to be considered in the design and interpretation of clinical trials with inhibitors of the PI3K pathway.

Original languageEnglish
Pages (from-to)5017-5019
Number of pages3
JournalClinical Cancer Research
Volume15
Issue number16
DOIs
Publication statusPublished - Aug 15 2009

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phosphoinositide 3-kinase mutations in breast cancer: A "good" activating mutation?'. Together they form a unique fingerprint.

  • Cite this